PRO Analysis Finds Manageable AEs With Olaparib in Early Breast Cancer
Cancer Network,
A patient reported outcome analysis of the phase 3 OlympiA trial found that treatment-emergent symptoms were easily resolved…
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2–Negative…
Overview of attention for article published in Journal of Clinical Oncology, February 2024
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (94th percentile)
-
Good Attention Score compared to outputs of the same age and source (74th percentile)
Readers on
- mendeley
- 46 Mendeley
